CHEK1 and ovarian carcinoma: The inhibition of HMGB3 in ovarian carcinoma cells that are resistant to cisplatin can result in the downregulation of ATR and CHK1 transcription, as well as the attenuation of the ATR/CHK1/p-CHK1 DNA damage signaling pathway (35).